Momentum Bioscience is focused on developing rapid tests for bloodstream infection in patients suspected of sepsis.
SepsiSTAT® is our direct-from-blood, rapid screening technology, providing actionable results for patients suspected of sepsis.
SepsiSTAT® contains our three proprietary capabilities:
1. Sensitive and universal microbial capture
2. Universal detection of viable microorganisms and microbial DNA extraction
3. Molecular characterisation
Only by using Momentum’s proprietary universal pathogen capture, detection & identification capabilities can all patients suspected of sepsis expect actionable results for bloodstream infection in <3 hours. Not days.
This will have a significant impact on patient management, the management of antibiotics and help mitigate the problem of increasing antimicrobial resistance.
How many organisations/clients currently utilise the service/solution across the UK?
Not yet a commercialised product.
Is there anything you would like to make delegates aware of ahead of the Managing Deteriorating Conditions Conference on 12th October?
Momentum has developed a test for the rapid, universal detection of viable organisms direct from whole blood in patients suspected of sepsis. This can be achieved in under 3 hours with a sensitivity of 1-10cfu/mL
What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
We are currently in research phase of product development with clinical studies ongoing. We seek collaborations to test the clinical effectiveness of our diagnostic assay for bloodstream infections and commercial partnerships to move to the next phase of our development.
Do you want to add any other key points?
The robust concentration and purification process of our test yields a lysate of 150µL which can then be used in downstream applications such as molecular ID, reporting a result before blood culture flags positive.